David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

NZ sharemarket up as Sanford rides the wave
Markets Market Close

NZ sharemarket up as Sanford rides the wave

Sanford’s result was its best in a decade.

Tom Raynel 15 May 2025
Why Xero is loyal to the ASX
Markets

Why Xero is loyal to the ASX

Cloud accounting firm 'happy to show up differently', CEO says.

NZX listing costs to fall
Markets

NZX listing costs to fall

The cost of providing PFI ranges from around $150,000 to $500,000, says NZX. 

Rebecca Howard 15 May 2025
Briscoe Group has plans for smaller ‘Metro stores’
Retail

Briscoe Group has plans for smaller ‘Metro stores’

There could be an opportunity for up to 15 new stores, COO Andrew Scott says.

Gregor Thompson 15 May 2025